After buying in candidate, Mannkind wraps up phase 1 trial of inhaled lung infection prospect

MannKind has wrapped up a phase 1 clinical trial of an inhaled formulation of clofazimine, teeing it up to talk to the FDA about advancing the candidate as a treatment for bacterial lung infections.